Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 7/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22094007 | 1.00 | MAT2A (0.40) | MAT2ACRHR1HCRTR1TRPV1BDKRB1 | |
| SCHEMBL31145387 | 0.84 | MAT2A (0.52) | MAT2A | |
| SCHEMBL22093459 | 0.84 | MAT2A (0.52) | MAT2A | |
| SCHEMBL22093749 | 0.79 | MAT2A (0.44) | MAT2AHCRTR1 | |
| SCHEMBL31145505 | 0.79 | MAT2A (0.44) | MAT2AHCRTR1 | |
| SCHEMBL22093203 | 0.79 | MAT2A (0.52) | MAT2ACRHR1TLR7 | |
| SCHEMBL31145436 | 0.79 | MAT2A (0.52) | MAT2ACRHR1TLR7 | |
| SCHEMBL29570844 | 0.72 | MAT2A (0.49) | MAT2A | |
| SCHEMBL22093344 | 0.72 | MAT2A (0.49) | MAT2A | |
| SCHEMBL31145484 | 0.72 | MAT2A (0.41) | MAT2AHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | IDEAYA BIOSCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240269143-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | GLAXOSMITHKLINE LLC | 2024-08-15 | — | — | US | disclosed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | MAT2A 3/4885CRHR1 2000/4885HCRTR1 3781/4885 |
| US-20240269143-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | PRMT1, PRMT6, MNAT1 | MAT2A 7/4885CRHR1 1021/4885HCRTR1 2815/4885 |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | MAT2A 2/4885CRHR1 4112/4885HCRTR1 4531/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885CRHR1 4112/4885HCRTR1 4531/4885 |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | PRMT1, PRMT6, MAT2A | MAT2A 3/4885CRHR1 2000/4885HCRTR1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.